Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.66 |
| ▸ | PGK1 | P00558 | 1/20 | 0.61 |
| ▸ | PGK2 | P07205 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885317 | 0.89 | ADORA2A (0.72) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL18820 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL2143756 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL9937290 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL14031852 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL18321891 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL13575801 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL13657986 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL20769831 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 | |
| Nelarabine SCHEMBL1818971 | 0.88 | CYP2C19 (0.71) | ADORA2AADORA2BCYP2C19SLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| EP-4023233-A2 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3518947-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064134-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2018-04-05 | — | — | WO | claimed |
| US-20180085411-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2018-03-29 | — | — | US | claimed |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | claimed |
| US-12521424-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4023233-B1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3518947-B1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-4023233-A2 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-4019029-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220088098-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2022-03-24 | — | — | US | disclosed |
| US-11253558-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS | 2022-02-22 | — | — | US | disclosed |
| US-20180085411-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2018-03-29 | — | — | US | disclosed |
| US-9771574-B2 | Apparatus for continuous directed evolution of proteins and nucleic acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-26 | — | — | US | disclosed |
| EP-3199630-A1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | President and Fellows of Harvard College (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2342336-B1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | HARVARD COLLEGE (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20150275202-A1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-01 | — | — | US | disclosed |
| US-9023594-B2 | Continuous directed evolution of proteins and nucleic acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-05 | — | — | US | disclosed |
| US-20110177495-A1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | ADORA2A 2027/4885ADORA2B 2136/4885CYP2C19 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.